FANELLI, Carmine Giuseppe
 Distribuzione geografica
Continente #
NA - Nord America 4.424
EU - Europa 3.718
AS - Asia 2.813
SA - Sud America 486
AF - Africa 51
OC - Oceania 24
Continente sconosciuto - Info sul continente non disponibili 6
Totale 11.522
Nazione #
US - Stati Uniti d'America 4.342
SG - Singapore 1.451
IE - Irlanda 594
UA - Ucraina 583
SE - Svezia 527
IT - Italia 499
CN - Cina 452
BR - Brasile 440
RU - Federazione Russa 424
HK - Hong Kong 377
DE - Germania 336
FI - Finlandia 220
VN - Vietnam 216
FR - Francia 157
GB - Regno Unito 129
KR - Corea 95
TR - Turchia 50
AT - Austria 49
PL - Polonia 47
CA - Canada 42
JP - Giappone 31
NL - Olanda 30
IN - India 27
ES - Italia 24
MX - Messico 24
AU - Australia 20
CH - Svizzera 20
ZA - Sudafrica 19
AR - Argentina 18
CZ - Repubblica Ceca 17
IQ - Iraq 15
UZ - Uzbekistan 15
BE - Belgio 14
BD - Bangladesh 13
GR - Grecia 12
ID - Indonesia 10
EC - Ecuador 8
JO - Giordania 8
LB - Libano 8
LT - Lituania 7
MA - Marocco 6
RO - Romania 6
KE - Kenya 5
PE - Perù 5
AE - Emirati Arabi Uniti 4
AZ - Azerbaigian 4
IL - Israele 4
NP - Nepal 4
PH - Filippine 4
TT - Trinidad e Tobago 4
CI - Costa d'Avorio 3
CL - Cile 3
CO - Colombia 3
CR - Costa Rica 3
DO - Repubblica Dominicana 3
DZ - Algeria 3
EE - Estonia 3
EG - Egitto 3
EU - Europa 3
KZ - Kazakistan 3
MY - Malesia 3
NZ - Nuova Zelanda 3
SA - Arabia Saudita 3
TN - Tunisia 3
TW - Taiwan 3
XK - ???statistics.table.value.countryCode.XK??? 3
AL - Albania 2
BA - Bosnia-Erzegovina 2
BW - Botswana 2
DK - Danimarca 2
GH - Ghana 2
HN - Honduras 2
HR - Croazia 2
IM - Isola di Man 2
KG - Kirghizistan 2
NG - Nigeria 2
PK - Pakistan 2
PS - Palestinian Territory 2
PY - Paraguay 2
RS - Serbia 2
TH - Thailandia 2
UY - Uruguay 2
VE - Venezuela 2
AF - Afghanistan, Repubblica islamica di 1
BB - Barbados 1
BG - Bulgaria 1
BH - Bahrain 1
BO - Bolivia 1
BY - Bielorussia 1
ET - Etiopia 1
GY - Guiana 1
HU - Ungheria 1
JM - Giamaica 1
KH - Cambogia 1
LC - Santa Lucia 1
LI - Liechtenstein 1
LK - Sri Lanka 1
LU - Lussemburgo 1
LV - Lettonia 1
MK - Macedonia 1
Totale 11.515
Città #
Singapore 925
Chandler 684
Dublin 594
Hong Kong 372
San Mateo 346
Boardman 274
Jacksonville 270
Santa Clara 196
Ashburn 193
Altamura 192
Medford 171
Princeton 169
Wilmington 144
Lawrence 129
Perugia 119
Munich 117
Beijing 115
Moscow 108
Seoul 93
Ann Arbor 88
Des Moines 86
Dong Ket 85
New York 82
Andover 78
Los Angeles 76
Helsinki 73
Saint Petersburg 53
Ho Chi Minh City 45
São Paulo 40
Piscataway 39
Brooklyn 35
Falls Church 35
Frankfurt am Main 33
Rome 33
Warsaw 29
Chicago 28
Izmir 28
Woodbridge 27
Hanoi 26
Tokyo 26
Norwalk 25
Nuremberg 24
Stockholm 24
Vienna 22
Turku 20
Dallas 18
Fremont 16
San Francisco 16
Amelia 15
Amsterdam 15
London 15
Milan 15
San Paolo di Civitate 15
Falkenstein 14
Redmond 14
Rio de Janeiro 14
Brussels 13
Montreal 13
Ankara 12
Denver 12
Atlanta 11
Brno 11
Auburn Hills 10
Mexico City 10
Orem 10
Shanghai 10
The Dalles 10
Boston 9
Poplar 9
Porto Alegre 9
Roubaix 9
Amman 8
Belo Horizonte 8
Bolton 8
Campinas 8
Curitiba 8
Goiânia 8
Houston 8
Johannesburg 8
Toronto 8
Bexley 7
Brasília 7
Chennai 7
Columbus 7
Cáceres 7
Guangzhou 7
Melbourne 7
Redwood City 7
Tashkent 7
Athens 6
Birmingham 6
Changsha 6
Den Haag 6
Frankfurt Am Main 6
Istanbul 6
Phoenix 6
Renton 6
San Diego 6
Baghdad 5
Bologna 5
Totale 6.895
Nome #
A randomized controlled trial to evaluate the efficacy of ultrasound-guided laser photocoagulation for treatment of benign thyroid nodules. 147
Adrenaline vs glucagon in the primacy of glucose counterregulation 147
Different brain responses to hypoglycemia induced by equipotent doses of long-acting insulin analog detemir and human regular insulin in humans 138
Hypoglycemia 132
Administration of neutral protamine Hagerdon insulin at bedtime versus with dinner in type 1 diabetes mellitus to avoid nocturnal hypoglycemia and improve control. A randomized, controlled trial. 128
An intensive lifestyle intervention in children with attention-deficit/hyperactivity disorder 121
18. Insulin required for prandial ghrelin suppression in humans 113
Blood-to-brain glucose transport and cerebral glucose metabolism are not reduced in poorly controlled type 1 diabetes 111
Effect of the amino acid alanine on glucagon secretion in non-diabetic and type 1 diabetic subjects during hyperinsulinaemic euglycaemia, hypoglycaemia and post-hypoglycaemic hyperglycaemia. 108
Physical activity habits and well-being among 6-year-old children: The “improving umbrian kids’ healthy lifestyle”, an uncontrolled pilot study project 106
Portal vein glucose sensors do not play a major role in modulating physiological responses to insulin-induced hypoglycemia in humans. 105
Effects of an Intensive Lifestyle Intervention to Treat Overweight/Obese Children and Adolescents 103
Blood-to-brain glucose transport, cerebral glucose metabolism, and cerebral blood flow are not increased after hypoglycemia 102
Short-term effects of the long-acting insulin analog detemir and human insulin on plasma levels of insulin-like growth factor-I and its binding proteins in humans. 101
Adrenergic mechanisms do not contribute to glucose counterregulation during acute insulin-induced hypoglycaemia in normal man. 100
Cognitive function in hypoglycaemia 99
Comparison of pharmacokinetics and-dynamics of the long-acting insulin analogs glargine and detemir at steady state in type 1 diabetes mellitus: a double-blind, randomized, cross-over study. 99
Prevention of hypoglycemia while achieving good glycemic control in type 1 diabetes: the role of insulin analogs 97
A novel surrogate index for hepatic insulin resistance. 97
Administration of Neutral Protamine Hagedorn insulin at bedtime versus dinner in Type 1 diabetes mellitus to avoid nocturnal hypoglycemia and improve control: a randomized, controlled trial. 97
Differential Effects of Adiposity on Pharmacodynamics of Basal Insulins NPH, Glargine, and Detemir in Type 2 Diabetes mellitus. 96
Insulin is required for prandial ghrelin suppression in humans 96
Uso dell’analogo ad azione rapida lispro con l’analogo ad azione ritardo glargine nel trattamento intensivo del T1DM 95
A randomized controlled trial to evaluate the efficacy of ultrasound-guided laser photocoagulation for treatment of benign thyroid nodules. 95
IMPACT OF NOCTURNAL HYPOGLYCEMIA ON HYPOGLYCEMIC COGNITIVE DYSFUNCTION IN TYPE 1 DIABETES 93
Intensive lifestyle intervention is particularly advantageous in poorly controlled type 2 diabetes 93
Counterregulatory hormone and symptom responses to insulin-induced hypoglycemia in the postprandial state in humans 91
Circulating palmitoleic acid is an independent determinant of insulin sensitivity, beta cell function and glucose tolerance in non-diabetic individuals: a longitudinal analysis 91
Pharmacokinetics and pharmacodynamic of therapeutic dose of basel insulins NPH, Glargine and Detemir after one week of daily administration at bedtime in Type 2 daibates: a randomized, cross-over study. 89
Early improvement of glucose tolerance after ileal transposition in a nonobese Type 2 diabetes rat model. 88
Body weight, not insulin sensitivity or secretion, may predict spontaneous weight changes in nondiabetic and prediabetic subjects: the RISC study. 88
Adrenergic mechanisms contribute to the late phase of hypoglycemic glucose counterregulation in humans by stimulating lipolysis. 88
Physical activity level and mediterranean diet adherence evaluation in older people - observational, uncontrolled, pilot study 88
Nocturnal blood glucose control in type I diabetes mellitus. 87
Fasting insulin has a stronger association with an adverse cardiometabolic risk profile than insulin resistance: the RISC study. 86
Intensive replacement of basal insulin in patients with type 1 diabetes given rapid-acting analogue at mealtime. A three month comparison between administration of NPH insulin four times daily and glargine insulin at dinner or bedtime. 85
Early improvement of glucose tolerance after ileal transposition in a non-obese type 2 diabetes rat model. 85
A randomized controlled trial to evaluate the efficacy of ultrasound-guided laser photocoagulation for treatment of benign thyroid nodules 85
Counterregulatory hormone and symptom responses to insulin-induced hypoglycaemia in the postprandial state in humans 82
Influence of the ACE gene insertion/deletion polymorphism on insulin sensitivity and impaired glucose tolerance in healthy subjects. 82
The dawn phenomenon in type 1 (insulin-dependent) diabetes mellitus: magnitude, frequency, variability, and dependency on glucose counterregulation and insulin sensitivity 82
Pivotal role of timely basal insulin replacement after metformin failure in sustaining long-term blood glucose control at a target in Type 2 diabetes. 82
Are three months multidisciplinary lifestyle intervention enough to get benefits on blood pressure in overweight/obese adults ? 82
Effects of a supervised nordic walking program on obese adults with and without type 2 diabetes: The C.U.R.I.A.Mo. Centre experience 81
Pharmacokinetics and pharmacodynamics of insulin glargine given in the evening as compared with in the morning in type 2 diabetes 79
Ghrelin is not necessary for adequate hormonal counterregulation of insulin-induced hypoglycemia 77
Glucagon: the effects of its excess and deficiency on insulin action 77
PHARMACOKINETIC AND PHARMACODYNAMIC HEAD-TO-HEAD COMPARISON OF CLINICAL, EQUIVALENT DOSES OF INSULIN GLARGINE 300 U/ML AND INSULIN DEGLUDEC 100 U/ML IN TYPE 1 DIABETES 77
Intensive replacement of basal insulin in patients with Type 1 diabetes mellitus given rapid-acting insulin analogue at meal-time: a three-month comparison between administration of NPH four times daily and glargine insulin at dinner or bedtime. 76
Evaluation of maximum oxygen consumption in obese adolescents before and after a multidisciplinary lifestyle intervention 76
Plasma sCD36 is associated with markers of atherosclerosis, insulin resistance and fatty liver in a nondiabetic healthy population. 76
Post-hypoglycaemic hyperketonaemia does not contribute to brain metabolism during insulin-induced hypoglycaemia in humans. 75
Premeal Insulin Treatment During Basal-Bolus Regimen in Young Children With Type 1 Diabetes 75
Hyperglycemia, Both Chronic and in Short-Term Peaks, Results in Rapid Increase of Expression of Monocyte Inducible Cyclooxygenase (COX-2) in Subjects with T2DM 74
Ipoglicemia: cause e prevenzione 73
Pharmacokinetics and pharmacodynamics of the long-acting insulin analog glargine after 1 week of use compared with its first administration in subjects with type 1 diabetes. 73
Brief twice-weekly episodes of hypoglycemia reduce detection of clinical hypoglycemia in type 1 diabetes mellitus. 73
Superiority of insulin analogues versus human insulin in the treatment of diabetes mellitus. 72
Effect of Short Term Intensive Lifestyle Intervention on Hepatic Steatosis Indexes in Adults with Obesity and/or Type 2 Diabetes 72
Circulatin ghrelin levels of visceral obese men are not modified by a short-term treatment with very low doses of GH replacement 71
Influence of Apolipoproteins on the Association Between Lipids and Insulin Sensitivity: A cross-sectional analysis of the RISC Study 71
Pharmacokinetics, pharmacodynamics, and modulation of hepatic glucose production with insulin glargine U300 and glargine U100 at steady state with individualized clinical doses in type 1 diabetes 71
Ricoveri per ipoglicemia grave in soggetti con diabete mellito di tipo 2: impatto clinico e costi sanitari 71
Counterregulatory responses in CSII 70
Effect of oral amino acids on counterregulatory responses and cognitive function during insulin-induced hypoglycemia in nondiabetic and type 1 diabetic people. 70
Pharmacokinetics and pharmacodynamics of subcutaneous injection of long-acting human insulin analog glargine, NPH insulin, and ultralente human insulin and continuous subcutaneous infusion of insulin lispro 70
Impact of BMI, Physical Activity, and Sitting Time Levels on Health-Related Outcomes in a Group of Overweight and Obese Adults with and without Type 2 Diabetes 70
Evaluation of the accuracy of a microdialysis-based glucose sensor during insulin-induced hypoglycemia, its recovery, and post-hypoglycemic hyperglycemia in humans. 69
Body composition and common carotid artery remodeling in a healthy population 69
Effect of cigarette smoking and of a transdermal nicotine delivery system on glucoregulation in type 2 diabetes mellitus 68
Impact of recent antecedent hypoglycemia on hypoglycemic cognitive dysfunction in nondiabetic humans. 67
Make your diabetic patients walk: long-term impact of different amounts of physical activity on type 2 diabetes. 66
Better long-term glycaemic control with the basal insulin glargine as compared with NPH in patients with Type 1 diabetes mellitus given meal-time lispro insulin 66
L’ipoglicemia silente nella pratica clinica quotidiana: come diagnosticarla, gestirla e prevenirla 66
Is physical activity a necessary element during Italian coronavirus disease emergency? Yes or no debate 66
Meticulous prevention of hypoglycemia normalizes the glycemic thresholds and magnitude of most of neuroendocrine responses to, symptoms of, and cognitive function during hypoglycemia in intensively treated patients with short-term IDDM. 65
Metabolism of insulin glargine after repeated daily subcutaneous injections in subjects with type 2 diabetes. 65
Glargine metabolism over 24 h following its subcutaneous injection in patients with type 2 diabetes mellitus: A dose–response study 65
Circulating ghrelin levels of visceral obese men are not modified by a short-term treatment with very low doses of GH replacement 65
Quando “i conti non tornano” (Caso clinico) G It Diabetol Metab 26:172-175 64
Mechanisms of insulin resistance after insulin-induced hypoglycemia in humans: the role of lipolysis. 64
Effect of storage temperature of insulin on pharmacokinetics and pharmacodynamics of insulin mixtures injected subcutaneously in subjects with type 1 (insulin-dependent) diabetes mellitus 64
Female Sex and Angiotensin-Converting Enzyme (ACE) Insertion/Deletion Polymorphism Amplify the Effects of Adiposity on Blood Pressure 64
Shift of glycaemic thresholds for cognitive function in hypoglycaemia unawareness in humans. 63
Pharmacokinetics and pharmacodynamics of NPH insulin in type 1 diabetes: The Importance of appropriate resuspension before subcutaneous injection 63
Greater Suppression of Glucagon, Lipolysis, and Ketogenesis with Insulin Glargine U300 as Compared with Glargine U100 in Type 1 Diabetes Mellitus 63
Circulating ghrelin levels of visceral obese men are not modified by a short-term treatment with very low doses of GH replacement. 62
Responses to hypoglycemia in diabetic autonomic neuropathy. 62
A multistep approach for the stratification of the risk of severe hypoglycemia in patients with type 2 diabetes 62
Nutritional Management of Athletes with Type 1 Diabetes: A Narrative Review 61
Insulin therapy and hypoglycemia: the size of the problem 61
Liver enzymes are associated with hepatic insulin resistance, insulin secretion, and glucagon concentration in healthy men and women. 59
Pharmacokinetics, pharmacodynamics and glucose counterregulation following subcutaneous injection of the monomeric insulin analogue [Lys(B28),Pro(B29)] in IDDM. 59
One hour post-load plasma glucose and 3 year risk of worsening fasting and 2 hour glucose tolerance in the RISC cohort 59
Insulin degludec, an ultra-longacting basal insulin, versus insulin glargine in basal-bolus treatment with mealtime insulin aspart in type 2 diabetes (BEGIN Basal-Bolus Type 2): a phase 3, randomised, open-label, treat-to-target non-inferiority trial. 58
Validation of a Counseling Strategy to Promote the Adoption and the Maintenance of Physical Activity by Type 2 Diabetic Subjects 57
La terapia insulinica nel diabete mellito tipo 2. 57
Thirty years of research on the dawn phenomenon: lessons to optimize blood glucose control in diabetes. 57
Insulin sensitivity and carotid intima-media thickness: relationship between insulin sensitivity and cardiovascular risk study. 57
Obesity and carotid artery remodeling 57
Totale 8.120
Categoria #
all - tutte 59.348
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 59.348


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/2021658 0 0 0 0 0 115 78 15 172 58 103 117
2021/20221.282 29 233 30 83 34 20 20 407 16 32 137 241
2022/20232.310 184 465 31 191 170 287 5 95 788 3 67 24
2023/2024982 54 105 43 33 8 8 195 14 77 39 185 221
2024/20252.340 36 230 81 126 366 65 59 182 513 167 304 211
2025/20262.480 360 325 266 603 779 147 0 0 0 0 0 0
Totale 11.835